Determination of the PPG and Insulin Responses of Rice Alone and Rice Consumed With Sugardown™

NCT ID: NCT03375398

Last Updated: 2017-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a partly controlled laboratory-based study comparing the short-term postprandial blood glucose and insulin responses produced by 3 test meals containing white rice alone or with SUGARDOWN™ (Galactomannan) in overweight adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STUDY SUMMARY This study was a partly controlled laboratory-based study comparing the short-term postprandial blood glucose and insulin responses produced by three test meals containing white rice alone or with SUGARDOWN™ (Galactomannan) in overweight adults. In the study, subjects were their own controls. Effects of the two test meals containing SUGARDOWN™ were compared to the effects produced by test meals containing an equal-carbohydrate portion of white rice alone (the control meal). The study used a repeated-measures design, such that every subject consumed each meal on two separate occasions, completing a total of six separate test sessions. Each subject completed their test sessions on separate weekday mornings at a similar time of day, as close as possible to the time they would normally eat breakfast.

SUBJECTS Ten healthy, non-smoking, overweight or obese subjects (4 females, 6 males) voluntarily participated in this study. The mean ± SD age of the subjects was 29.2 ± 3.3 yr (range: 25.6 - 36.8 yr), and their mean ± SD body mass index value was 27.3 ± 1.1 kg/m2 (range: 25.5 - 28.7 kg/m2).

Volunteers were given detailed written and verbal information about all of the study's inclusion criteria and experimental procedures. If the volunteers decided that they would like to participate in the study, they were asked to come to the research centre on another morning, where they completed a detailed screening questionnaire that assessed their current health status and medical history. In order to participate in the study, the volunteers had to meet the inclusion criteria listed below. All suitable volunteers that were invited to participate in the study were required to sign a detailed subject information sheet and a consent form before commencing any experimental procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postprandial Hyperglycemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

SUGARDOWN™ Galactomannan Postprandial blood glucose Insulin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3 tablets Sugardown™

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™

Group Type EXPERIMENTAL

Sugardown™

Intervention Type DIETARY_SUPPLEMENT

Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water

Rice only

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice

Group Type PLACEBO_COMPARATOR

Rice

Intervention Type DIETARY_SUPPLEMENT

Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water

6 tablets Sugardown™

Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™

Group Type EXPERIMENTAL

Sugardown™

Intervention Type DIETARY_SUPPLEMENT

Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rice

Test food #1: White Rice \<63.0 g (dry) Jasmine rice consumed together with 250 mL water

Intervention Type DIETARY_SUPPLEMENT

Sugardown™

Test food #2: White Rice \< 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice \< 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BTI320 PAZ320 BTI320 PAZ320

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 25-65 years.
* Non-smoker.
* Stable body weight within the overweight weight range for their height (BMI values \> 25 kg/m2).
* Normal dietary habits; not dieting or eating in an overly restrictive fashion in the past 3 months.
* A regular pattern of low to moderate physical activity.
* Able to fast for ≥ 10 hours the night before each test session.
* Able to refrain from eating a legume-based evening meal or drinking alcohol the day before each test session.
* Finds the test foods suitable for consumption within 12 minutes.
* Participant covered by social security or a similar system.
* Not taking any treatment for anorexia, weight loss, or any form of treatment or medication likely to interfere with metabolism or dietary habits.
* Signed the informed consent form for the study.

Exclusion Criteria

* Currently following a restrictive diet (low-calorie, low-carbohydrate, vegan).
* Any clinically significant physical or mental illness.
* Suffering from a food allergy or serious food intolerance.
* Regularly taking prescription medication other than standard contraceptive medication.
* Females who are currently pregnant, breast-feeding, trying to become pregnant or not using an acceptable contraceptive.
* Participating in another clinical trial or participated in another clinical trial within the last week.
* Undergoing general anaesthesia in the month prior to inclusion.
* Subject in a situation, which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.
Minimum Eligible Age

25 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boston Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jennie Brand-Miller, Prof.

Role: PRINCIPAL_INVESTIGATOR

Human Nutrition Unit School of Molecular Bioscience, University of Sydney, Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAZ320-001

Identifier Type: -

Identifier Source: org_study_id